Evercore ISI Group Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $134

Benzinga Newsdesk www.benzinga.com Positive 92.1%

Neg 0% Neu 0% Pos 92.1%

Evercore ISI Group analyst Gavin Clark-Gartner maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $120 to $134.